Thursday, October 29, 2009

Newly approved drugs(FDA September-October 2009)

  • Here are some newly approved drugs, vaccines and some new indications for old drugs.
Ofatumumab
CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia.

Pazopanib
kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma

Cervarix
human papillomavirus bivalent (types 16 and 18)
preventative cervical cancer vaccine for the prevention of cervical pre-cancers
and cervical cancer associated with oncogenic human papillomavirus
(HPV) types 16 and 18 in girls and young women (aged 10-25)

Berinert (C1-esterase inhibitor (human)
plasma derived C1 Esterase Inhibitor indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients.

Ustekinumab
human monoclonal antibody for the treatment of moderate to severe plaque psoriasis.

Pralatrexate
folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)

Influenza A (H1N1) 2009 Monovalent Vaccine
 is an inactivated influenza virus vaccine indicated for active immunization of persons ages 18 years of age and older against influenza disease caused by pandemic (H1N1) 2009 virus

Telavancin
bactericidal, once-daily injectable antibiotic for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Bepotastine
antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.

Guanfacine
a nonstimulant selective alpha-2A-receptor agonist for the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)

Source- www.drugs.com

Posted via web from Inquisitives' posterous

No comments: